Navigation Links
XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007

Company Also to Host Drug-Eluting Stent Symposium and Analyst Webcast

MENLO PARK, Calif., Oct. 16 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that 2-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company's investigational Custom NX(R) drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.

In addition, the company will conduct a number of activities during the meeting including an analyst webcast and teleconference to review the CUSTOM I and CUSTOM II clinical data, an evening drug-eluting stent symposium, and an exhibition at booth 6097 on Level 2 of the Washington Convention Center.

Schedule of Events

Sunday, October 21

Event: The Drug-Eluting Stent Summit: The XTENT CUSTOM Biolimus-Eluting

Modular Stent Program (Focus on Multivessel and Diffuse Disease)

Pieter Stella, M.D., Director of Cardiology, University Medical Center,

Utrecht, Netherlands, will present a historical overview and current

perspective on the treatment of multivessel coronary disease and the

treatment of long lesions. An overview of the Custom NX(R) DES System with

respect to the treatment of multivessel and diffuse disease will be

discussed, along with the one-year follow-up results of the CUSTOM II


Time/Location: 3:16-3:26 p.m. EDT; Ballroom C, 3rd Floor, Washington

Convention Center

Event: Evening Symposium -- Delivering Safety to Today's Patients

Professor Eberhard Grube, M.D., Chief of Cardiology at the HELIOS Heart

Center in Siebgurg, Germany and principal investigator of the CUSTOM I and

II clinical trials, will review the results to date from Biolimus A9(R)

DES clinical trials and registries. Professor Grube will present two-year

results from the CUSTOM I clinical trial and one-year results from the

CUSTOM II clinical trial.

Bernard de Bruyne, M.D. Ph.D, Cardiovascular Center, OLV Hospital in

Aalst, Belgium, will provide an overview of the Custom NX technology in a

presentation titled "XTENT Custom NX DES Systems: A Novel Approach to the

Percutaneous Treatment of Coronary Artery Disease (CAD)."

Time/Location: 8:00-10:00 p.m. EDT; Renaissance Washington, D.C. Hotel,

Grand Ballroom, 999 Ninth Street NW

Monday, October 22

Event: Analyst Webcast and Teleconference on CUSTOM I and CUSTOM II Data

XTENT will host a webcast and teleconference call to review the CUSTOM I

and CUSTOM II data presented on Sunday. The teleconference and slide

presentation can be accessed via the investor relations section of the

company's website at or by calling

888-663-2258 (from the U.S.), 913-312-1277 (international). Please dial in

or access the website five to ten minutes prior to the beginning of the

call. The webcast will be archived on the website for a minimum of three

months, and can be accessed at the investor relations portion of the

company's website at

Time/Location: 7:00 a.m. EDT


XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT Custom NX DES Systems have not been approved for sale by any regulatory authority.

Information about XTENT is available at our website at

Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
2. The Past, Present and Future of HLA Typing
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
(Date:11/29/2015)... Germany , Nov. 29, 2015 /PRNewswire/ ... Imaging invites attendees to experience the most complete mobile ... highlight on display is Ziehm Vision RFD 3D, the ... a 16 cm edge length per scan volume. In ... the first fully motorized mobile C-arm in four axes ...
(Date:11/27/2015)... 2015 Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... Une nouvelle approche consistant à combiner l,immunothérapie au ...    Clinical Cancer Research . ...
(Date:11/27/2015)... DUBLIN , Nov. 27, 2015 Research ... of the "Global Intrauterine Devices Market 2015-2019" ... --> In this report, the author ... intrauterine devices market for 2015-2019. To calculate the market ... of following type of products: Hormonal IUDs and copper ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... ... Key Housing, a top-rated corporate housing service for the San Jose and ... In showcasing this featured apartment community in San Jose, Key Housing is helping those ... find housing suitable to their needs by showcasing quality housing. , “San Jose many ...
(Date:11/28/2015)... , ... November 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST until ... most savings. , With possible savings of up to 20% off orders $80 or more ... of the website every few hours. , As a competitive e-commerce website for skin care ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... and the University of British Columbia suggested that laws requiring bicyclists to wear helmets ... that part of the reason for the controversial conclusion is that, while helmets have ...
(Date:11/27/2015)... PITTSBURGH, PA (PRWEB) , ... November 27, 2015 ... ... to be a safe and convenient way to dispense prescription medications at home, ... safe and effective way to monitor and dispense prescription medications. In doing so, ...
(Date:11/27/2015)... ... 27, 2015 , ... ProSidebar: Fashion is a set of 30 ... ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX production. ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease of ...
Breaking Medicine News(10 mins):